A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL (NCT03571568)
Phase 1/2a Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab
🩺 Plain-English Summary (8th-Grade Level)
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab
Who can join: Review the eligibility criteria below.
Location: Emory University Hospital — Atlanta, Georgia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (27 Sites)
Showing the first 25 of 27 sites.
- Emory University Hospital — Atlanta, Georgia
- Norton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405 — Louisville, Kentucky
- Hospital São Rafael — Salvador, Estado de Bahia
- Hospital de Clínicas de Porto Alegre — Porto Alegre, Rio Grande do Sul
- Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer — Curitiba,
- Ruschel Medicina e Pesquisa Clínica — Rio de Janeiro,
- A.C. Camargo Cancer Center — São Paulo,
- Hospital Amaral Carvalho — São Paulo,
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo — São Paulo,
- Hospital Israelita Albert Einstein — São Paulo,
- Hospital Samaritano — São Paulo,
- Hospital Sírio-Libanês — São Paulo,
- Krankenhaus Nordwest Klinik für Onkologie und Hämatologie — Frankfurt am Main, Hesse
- Robert Bosch Hospital, Dep of Hematology, Oncology and Palliative care — Stuttgart,
- Szpital Specjlistyczny — Grudziądz,
- Małopolskie Centrum Medyczne — Krakow,
- Hospital ICO, Trias i Pujol — Badalona, Barcelona
- Hospital de la Santa Creu i Sant Pau, Dep Hematologia — Barcelona,
- Hospital Universitari Vall d'Hebron — Barcelona,
- Institut Català d'Oncologia, L'Hospitalet de Llobregat — Barcelona,
- Hospital General Universitario Gregorio Marañon-Oncología Médica — Madrid,
- Hospital Universitario HM Sanchinarro — Madrid,
- University Hospital Fundacion Jimenez Diaz — Madrid,
- Hospital Universitario Virgen de la Arrixaca — Murcia,
- Hospital University Virgen Macarene — Seville,
📞 Contact the Study Coordinator
Phone: +46706126618
Email: erika.bageman@bioinvent.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Indolent B-Cell Non-Hodgkin Lymphoma
- Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma — Scottsdale, Arizona
Explore by condition: All Indolent B-Cell Non-Hodgkin Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.